Common use of 131 Additional Definitions Clause in Contracts

131 Additional Definitions. The following table identifies the location of definitions set forth in various Sections of this Agreement: Accounting Firm 8.9(b)(i) Agreement Preamble Agreement Payments 8.10 Alliance Manager 3.7 Alternative Antibody Review Period 2.7(c) Anti-Corruption Laws 11.7(a)(i) Antitrust Filings 14.1 Bankrupt Party 14.3(d)(ii)(1) Biosimilar Applications 13.10(a) Biosimilar Reduction Trigger 8.5(c)(iii) Claim 12.1 CMO 6.1(a) Competitive Licensed Product 8.5(c)(iv) Controlling Party 13.10(a)(i) Data Package 2.11(b) Data Protection Laws 11.4(c) Development Matter 3.2(b) Development Plan 4.2 Dispute 15.5(a) Enforcement Action 13.3(b) Enforcing Party 13.3(b) Excluded Claim 15.5(e) Execution Date Preamble Global Development Plan 4.2 Global Safety Database 5.4(b) HKIAC 15.5(a) Indemnified Party 12.3 Indemnifying Party 12.3 Independent Activity Costs 5.3(c) Joint Patent Rights 13.1(c) JCMC 3.3(a) JDC 3.2(a) JSC 3.1 Losses 12.1 Manufacturing Dispute 3.3(c) Manufacturing Matter 3.3(c) New Clinical Trial 4.1(c) [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. New Licensed Product Royalty Term 8.5(b)(iii) Non-Controlling Party 13.10(a)(i) Notice of Dispute 15.5(a) Objecting Party 3.5(c) Opt-In Date 2.11(b) Opt-In Notice 2.11(b) Opt-In Period 2.11(b) Opt-In Product Clinical Supply Agreement 6.2(a) Opt-In Product Commercial Supply Agreement 6.2(d) Opt-In Product Manufacturing Technology Transfer 6.2(b) Opt-In Product Technology Transfer Plan 6.2(b) Opt-In Product Royalty Term 8.5(b)(ii) Opt-In Right 2.11(a) Opt-In Product Third Party Payments 2.11(b) Opt-In Termination Territory 14.4(c)(i) Opt-In Terminated Product 14.4(c)(i) Party(ies) Preamble Patent Term Extension 13.5 Payee Party 8.4(b) Paying Party 8.4(b) Personal Data 11.4(c) Pharmacovigilance Agreement 5.4(a) Press Release 10.3(a) Prior CDAs 9.4 Product Infringement 13.3(a) Product Marks 13.8 Public Official 11.7(d) Publication 10.1(a) Purple Book 13.6 RC48 Clinical Supply Agreement 6.1(a) RC48 Commercial Supply Agreement 6.1(b)(i) RC48 Licensed Product Royalty Term 8.5(b)(i) RC48 Manufacturing Technology Transfer 6.1(b)(ii) RC48 Manufacturing Technology Transfer Plan 6.1(b)(ii) RC48 Terminated Product 14.4(b)(i) Remedial Action 5.6 RemeGen Preamble RemeGen Existing CMO Agreements 11.2(o) RemeGen Existing In-Licenses 11.2(v) [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. RemeGen Indemnitee(s) 12.1 RemeGen Continuing Technology Transfer 2.12(a) RemeGen Initial Technology Transfer 2.12(a) RemeGen Technology Transfer 2.12(a) Review Period 10.1(a) ROFN Notice 2.5 Royalty Floor 8.5(c)(v) Rules 15.5(a) Safety Auditing Party 5.5 Seagen Preamble Seagen [ * ] Technology Transfer 2.12(b)(ii) Seagen Existing CMO Agreements 11.3(f) Seagen Existing In-Licenses 11.3(e) Seagen Initial Technology Transfer 2.12(b)(ii) Seagen Linker Invention 1.114 Seagen RC48 [ * ] Technology Transfer 2.12(b)(i) Seagen Technology Transfer 2.12(b)(ii) Seagen Indemnitee(s) 12.2 Securities Regulators 10.3(c) Taxes 8.10 Technology Transfer Plan 2.12(a) Term 14.2 Third Party License(s) 8.5(c)(ii) Transfer Taxes 8.10 U.S. Bankruptcy Code 14.3(d)(ii)(1)

131 Additional Definitions. The In addition, each of the following table identifies terms shall have the location of definitions set forth meaning described in various Sections the corresponding Section of this Agreement: Accounting Firm 8.9(b)(iDefinitive LRRK2 Agreement identified below. Acquired Party 6.8.4 Cost-Profit Share 7.7 Acquiring Party 6.8.3 Cost-Profit Sharing Country 7.7 Adverse Ruling 13.2.2 Cost-Profit Sharing Product 7.7 [***] [***] Debarred Entity 11.1.6(b) [***] [***] Debarred Individual 11.1.6(a) Alliance Manager 2.6 Declining Party 3.1.4(c) [***] [***] Definitive LRRK2 Agreement Preamble Agreement Payments 8.10 Alliance Manager 3.7 Alternative Antibody Review Period 2.7(cBIG Preamble Denali Preamble BIMA Preamble [***] [***] Biogen Preamble Denali Commercialization Opt-Out 7.8.1(a) AntiBiogen Executive 2.4.5(c) Denali Development Opt-Corruption Laws 11.7(a)(iOut 7.8.1(a) Antitrust Filings 14.1 Bankrupt Party 14.3(d)(ii)(1[***] [***] Denali Indemnitees 12.1 Biogen Indemnitees 12.2 Denali Opt-Out 7.8.1(a) Biosimilar Applications 13.10(a[***] [***] Denali Opt-Out Notice 7.8.1(a) Biosimilar Reduction Trigger 8.5(c)(iii[***] [***] Development Expense Report 7.7.2(a) Claim 12.1 CMO 6.1(a) Competitive Licensed Product 8.5(c)(iv) Controlling Party 13.10(a)(i) Data Package 2.11(b) Data Protection Laws 11.4(c) Development Matter 3.2(b) Development Plan 4.2 [***] [***] Dispute 15.5(a) Enforcement Action 13.3(b) Enforcing Party 13.3(b) Excluded Claim 15.5(e) Execution 14.6 Breach Notice 13.2.1 Effective Date Preamble Breaching Party 13.2.1 [***] [***] [***] [***] Excluded Entity 11.1.6(c) Chief Executive Officers 14.6.1 Excluded Individual 11.1.6(c) CMC Working Group 4.5 Existing Denali Agreement 1.64 CMO Supply Agreement 4.2 Final Royalty Report 7.6.7(b) Co-Commercialization Activities 5.1.4(a) Finance Working Group 7.7.6 Co-Commercialization Activities End Date 5.1.4(c) Force Majeure Article 14 Co-Commercialization Agreement 5.1.4(b) GAAP 1.1 Co-Commercialization Territory Regulatory Filings 3.3.2(c) [***] [***] [***] [***] [***] [***] Co-Funding End Date 7.8.1(a) Global Development Plan 4.2 Global Safety Database 5.4(bBudget 3.1.1(b) HKIAC 15.5(aCommercialization Wind-Down Period 13.7.2(b) [***] [***] [***] [***] ICH 1.61 Consolidated Report 7.7.3 Indemnification Claim Notice 12.4 Convicted Entity 11.1.6(d) Indemnified Losses 12.1 Convicted Individual 11.1.6(d) Indemnified Party 12.3 Indemnifying Party 12.3 12.4 Independent Activity Costs 5.3(c) Joint Patent Rights 13.1(c) JCMC 3.3(a) JDC 3.2(a) JSC 3.1 Losses 12.1 Manufacturing Dispute 3.3(c) Manufacturing Matter 3.3(c) New Clinical Trial 4.1(c) [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. New Licensed Product Royalty Term 8.5(b)(iii) Non-Controlling Party 13.10(a)(i) Notice of Dispute 15.5(a) Objecting Party 3.5(c) Study 3.1.4 Opt-In Date 2.11(b) Opt-In Notice 2.11(b) Opt-In Period 2.11(b) Opt-In Product Clinical Supply Agreement 6.2(a) Opt-In Product Commercial Supply Agreement 6.2(d) Opt-In Product Manufacturing Technology Transfer 6.2(b) Opt-In Product Technology Transfer Plan 6.2(b) Opt-In Product Royalty Term 8.5(b)(ii) Opt-In Right 2.11(a) Opt-In Product Third Party Payments 2.11(b) Opt-In Termination Territory 14.4(c)(i) Opt-In Terminated Product 14.4(c)(i) Party(ies) Preamble Patent Term Extension 13.5 Payee Party 8.4(b) Paying Party 8.4(b) Personal Data 11.4(c) Pharmacovigilance Agreement 5.4(a) Press Release 10.3(a) Prior CDAs 9.4 Product Infringement 13.3(a) Product Marks 13.8 Public Official 11.7(d) Publication 10.1(a) Purple Book 13.6 RC48 Clinical Supply Agreement 6.1(a) RC48 Commercial Supply Agreement 6.1(b)(i) RC48 Licensed Product Royalty Term 8.5(b)(i) RC48 Manufacturing Technology Transfer 6.1(b)(ii) RC48 Manufacturing Technology Transfer Plan 6.1(b)(ii) RC48 Terminated Product 14.4(b)(i) Remedial Action 5.6 RemeGen Preamble RemeGen Existing CMO Agreements 11.2(o) RemeGen Existing In-Licenses 11.2(v) [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. RemeGen Indemnitee(s) 12.1 RemeGen Continuing Technology Transfer 2.12(a) RemeGen Initial Technology Transfer 2.12(a) RemeGen Technology Transfer 2.12(a) Review Period 10.1(a) ROFN Notice 2.5 Royalty Floor 8.5(c)(v) Rules 15.5(a) Safety Auditing Party 5.5 Seagen Preamble Seagen [ * ] Technology Transfer 2.12(b)(ii) Seagen Existing CMO Agreements 11.3(f) Seagen Existing In-Licenses 11.3(e) Seagen Initial Technology Transfer 2.12(b)(ii) Seagen Linker Invention 1.114 Seagen RC48 [ * ] Technology Transfer 2.12(b)(i) Seagen Technology Transfer 2.12(b)(ii) Seagen Indemnitee(s) 12.2 Securities Regulators 10.3(c) Taxes 8.10 Technology Transfer Plan 2.12(a) Term 14.2 Third Party License(s) 8.5(c)(ii) Transfer Taxes 8.10 U.S. Bankruptcy Code 14.3(d)(ii)(1Out Country 7.8.1(a)